At the beginning of the millennium, the finding that HER2-overexpressing breast cancer could be targeted with the anti-HER2 monoclonal antibody trastuzumab, combined with chemotherapy, resulting in a therapeutic improvement [22] paved the way to HER2-targeted therapies. Here, ERBB2 is linked to breast carcinoma.